Known and novel histaminergic H-1- and H-2-receptor agonists were investigated as potentially potent and selective brain-penetrating compounds. Structural modifications were introduced in an attempt to favour passive diffusion across the blood-brain barrier by reducing hydrogen-bonding ability according to a previously developed model. While no novel compound was identified which satisfied our requirements for a brain-penetrating agonist, betahistine 14 and 2-(thiazol-2-yl)ethylamine 16 can be regarded as H-1-receptor agonists with moderate brain-penetrating ability, of potential value as pharmacological tools. A novel histamine analogue, N,N-bis-2-[4(5)-imidazolyl]ethyl)amine 25 is reported which. although unlikely to be brain penetrant, was found to be equipotent with histamine at H-1- and H-1-receptors.
MANOURY, PH. M.;BINET, J. L.;DUMAS, A. P.;LEFEVRE-BORG, F.;CAVERO, I., J. MED. CHEM., 1986, 29, N 1, 19-25
作者:MANOURY, PH. M.、BINET, J. L.、DUMAS, A. P.、LEFEVRE-BORG, F.、CAVERO, I.
DOI:——
日期:——
USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER
申请人:Exelixis, Inc.
公开号:EP2056829A2
公开(公告)日:2009-05-13
PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF